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INTRODUCTION
Renal transplantation is important for hemodynamic manage-
ment and fluid volume control (1). We usually use continuous
hemodynamic monitoring, arterial line (A- line) and central venous
catheter (CVC), as a guide fluid management and to adjust inotropic
and/or vasopressor agents. However, both A-line and CVC re-
quire invasive catheters.
The ClearSight system (Edwards Lifesciences Cop, Irvine, CA,
USA) is a device used for measuring arterial blood pressure con-
tinuously and noninvasively through finger- cuffed technology (2).
Not only finger-cuff -based monitoring of blood pressure (FBP),
but the ClearSight system provide heart rate (HR), stroke volume
(SV), cardiac output (CO), cardiac index (CI), stroke volume index
(SVI), stroke volume variation (SVV), systemic vascular resistance
(SVR), and systemic vascular resistance index (SVRI) (3). It is
noninvasive measurement.
Therefore, we investigated the ClearSight system may be useful-
ness in renal transplantation recipient as a reliable and totally
noninvasive method of fluid measurement without CVC.
CASE REPORT
The recipient of the renal transplantation in this study was a 41-
year-old male, with a weight of 91.2 kg and height of 163.5 cm with
end-stage renal failure. He had a history of multicystic renal cyst,
multicystic liver cyst, and hypertension. His routine blood reports
were normal, except for renal dysfunction (BUN 36.3 mg/dl, Cr
7.29 mg/dl). The patient’s electrocardiogram (ECG) showed a soli-
tary T- wave inversion in III. The chest X-ray was normal. His
echocardiography report showed that he had a functional left
ventricle with an ejection fraction of 75%, mild left ventricular (LV)
hypertrophy, and LV diastolic dysfunction, and not reduced car-
diac function. He started hemodialysis in November 2016 from a
distal radiocephalic arteriovenous fistula (AVF) on the left arm.
Because of the symptoms of nausea and vomiting, the patient
experienced after every hemodialysis, treatment was short-
ened. It was determined that he could receive renal transplant
from his mother, under general anesthesia. His intravenous access
was established using an 18-G cannula on the right hand. After a
radial artery was cannulated (A-line), the figure cuff of the ClearSight
device (Edwards Lifesciences Cop, Irvine, CA, USA) was placed
around the patient’s right hand index finger. Pulse oximetry, ECG,
non- invasive blood pressure (NBP), end tidal CO2, core body tem-
perature by a rectum probe, hourly urine output, and finger-cuff -
based monitoring of blood pressure (FBP), cardiac output (CO),
stroke volume variation (SVV) were measured.
Anesthesia was induced with DIV remifentanil 0.3 µg/kg/ min
and IV propofol 1 mg/kg. Intubation was facilitated with IV rocu-
ronium 60 mg. Anesthesia was maintained with sevoflurane, O2,
air, and rocuronium as the muscle relaxant, in combination with
remifentanil 0.1 -0.3 µg/ kg/ min and fentanyl. We managed the
fluid volume with SVV obtained with the ClearSight to predict fluid
responsiveness. Stroke volume variation may be a useful pa-
rameter to predict hypovolemia and fluid responsiveness during
renal transplantation (3).
Until clamping the renal artery, the infusion volume is the
maintenance volume and the bleeding volume. We maintained
FBP 90/55 mmHg, heart rate (HR) 60 bpm, SVV 12%, stroke volume
(SV) 86mL/b and CO 5.2 L/min. As SVV is modified by lung compli-
ance and ventilatory management, we setted ventilatory control to
tidal volume 600 mL, positive end-expiratory pressure 0 mmHg,
and peak airway pressure 18mmHg. We usually managed, before
declamping the renal artery, a central venous pressure (CVP) of
12 - 15 mmHg were ensured with the help of generous hydration. In
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this case, CVC was not inserted, we defined systolic FBP as being
maintained above 120 mmHg and SVV of 4-6% of increasing SV and
CO, instead of CVP. This volume expansion is associated with in-
creased renal blood flow and improved graft function. Just before
anastomosis and clamp release, we decreased the SVV by 4% (abso-
lute percentage value), increased SV and CO, and maintained
FBP to provide adequate perfusion to the transplanted kidney. We
maintained FBP at 120-136/65-70 mmHg, HR 68-76 bpm, SVV 4-
6%, SV 106-120 mL/b and CO 7.2-9.7 L/min. Furosemide was
given to improve graft viability and ensure diuresis. The patient’s
systolic FBP was kept above 120 mmHg until the end of the sur-
gery, and about 3000 mL of crystalloids and 100 mL of colloids
(20% human serum albumin) were infused. There was adequate
urine output of 900 mL per hour after reperfusion. The patient was
extubated uneventfully, after complete reversal of muscle paraly-
sis. We made use of a balanced anesthetic technique and stringent
monitoring standards to ensure a successful outcome for the pa-
tient. On the 11 postoperative day, the patient went home with a
healthy functioning kidney (BUN 35.7 mg/dl, Cr 2.45 mg/dl).
DISCUSSION
Renal transplantation is important for hemodynamic manage-
ment and fluid volume control. Our goals for perioperative manage-
ment were to maintain stable hemodynamics throughout the pro-
cedure, perform adequate infusion, maintain perfusion for the
transplanted solitary kidney, and to provide adequate analgesia for
the patient. Therefore, continuous hemodynamic monitoring, A-
line and CVC, is of use as a guide fluid management and to adjust
inotropic and/or vasopressor agents. However, both A-line and
CVC require invasive catheters and therefore increase the risk of
catheter infection, bleeding, deep venous thrombosis, and pneu-
mothorax (2).
The ClearSight system uses photoplethysmography and an in-
flatable cuff placed around a finger (Figure 1). This measures fin-
ger arterial pressure directly from the finger cuff using a volume-
clamp method, from which brachial arterial pressure is recon-
structed using waveform filtering with pressure level correction
(4). The ClearSight system provide continuous noninvasive FBP,
HR, SV, CO, cardiac index (CI), stroke volume index (SVI), SVV,
systemic vascular resistance (SVR), and systemic vascular resis-
tance index (SVRI). Stroke volume is estimated based on arterial
pressure waveforms obtained from the finger artery, and multi-
plied by the pulse to express CO (3). Respiration-related changes in
the SV (SVV) are serially expressed. Stroke volume variation may
become a parameter of optimized hemodynamics and fluid respon-
siveness (3).
Fig 2. Vital record with ClearSight. First arrow shows the renal artery clamped. Second arrow is the renal artery declamped.
SBP = systolic blood pressure, mmHg. SV = stroke volume, mL/b. MAP = mean arterial pressure, mmHg. DBP = diastolic blood pressure,
mmHg. PR = pulse rate, bpm. SVV = stroke volume variation, %. CO = cardiac output, L/min.
Fig 1. The ClearSight device
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Our main goal during the renal transplantation, to promote the
function of the transplanted kidney and maintain an adequate vol-
ume of blood flow in the transplanted kidney to prevent acute
tubular necrosis(5). Therefore, before clamping the renal artery, we
managed a normal FBP and a SVV of 10-13% using the ClearSight
system. After declamping, the kidney was perfused, maintained at a
high normal FBP and co-hydration to maintain kidney blood
flow, to get urine volume, SVV decreased by 4-6% (absolute per-
centage value). Although we used SVV to fluid volume control, it
should be management from correlation between SVV and SVI.
Further research is needed to determine whether this manage-
ment (SVV of 4-6% of increasing SV and CO) is optimal to prevent
the postoperative acute tubular necrosis.
The accuracy of FBP compared with NBP and invasive blood
pressure was not inferior in this case. The bias between ClearSight
was less than 5 mmHg with NBP and ABP. However, Hohn evalu-
ated non- invasive continuous arterial pressure monitoring did not
sufficiently replace invasive measurements in critically ill patients
(6). In their study, critically ill patients experienced edema and had
continuous norepinephrine administration that may have reduced
peripheral blood flow, affecting the non- invasive measurements.
Our patient had adequate cardiac function and was not in the
critically ill state, ClearSight was a reliable monitor, but, further
study is needed using various patients.
In fully sedated and mechanically ventilated patients, SVV can be
considered as a reliable monitor of fluid responsiveness(2). Stroke
volume variation is the most reliable predictor of optimized hemo-
dynamics and fluid responsiveness, many studies have reported its
accuracy (7-9). In this case, we did not fhe CVC to reduce invasive
catheters. It might be more better to compare SVV and CVP. It
would have been interesting to know how the SVV-guided fluid
management affected CVP (10).
Recent studies have shown the feasibility of noninvasive and con-
tinuous blood pressure measurements during surgical proce-
dures. However, accuracy and precision are still debated (11). This
case demonstrated ClearSight has potential to improve patient
monitoring in hemodynamically stable patients who receive kidney
transplantation under general anesthesia.However, further studies
are needed to provide reliable information for the intraoperative
management of high risk patients during renal transplantation
without the need for invasive arterial cannulation and central
venousr catheter.
In addition, we have used the ClearSight in living renal trans-
plantation. We think that it is also useful in cadaveric renal trans-
plantations. Transfusion management of cadaveric renal transplan-
tation is more difficult than living renal transplantation. Because
oliguria often continues even after surgery, it does not load infusion
easily (12). We also want to evaluate the effectiveness of the
ClearSight device in cadaveric renal transplantations.
CONCLUSION
ClearSight is a less- invasive circulatory monitoring system that
may improve the safety of anesthetic management during renal
transplantation. Further research, with the use of the ClearSight
device, in renal transplantation will help to determine the safety and
efficacy.
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